复合型小细胞肺癌的诊断及治疗方法  

Diagnosis and treatment of compound small cell lung cancer

作　　者：高冠斌 姚兵[1] 李勇[1] 李忠诚[1] 杨永良[1] GAO Guan-bin;YAO Bing;LI Yong;LI Zhong-cheng;YANG Yong-liang(Department of Cardio-Thoraicic Surgery,the Affiliated Hospital of QingHai University,Qinghai 810000,Xining,CHINA)

机构地区：[1]青海大学附属医院心胸外科

出　　处：《海南医学》2019年第17期2285-2289,共5页Hainan Medical Journal

摘　　要：随着人们对小细胞肺癌认识水平及获取病理标本技术的提高,病理类型提示为小细胞肺癌混合有非小细胞肺癌成分受到众多研究者的关注,即复合型小细胞肺癌(C-SCLC)。复合型小细胞肺癌是一种恶性程度极高的肿瘤,临床上对放化疗均较敏感,缓解率高,但治疗后往往发生耐药并复发,且预后较差。近年来C-SCLC诊治取得了一定成果,但仍然存在着众多难题,综述国内外关于该方向的研究成果,并探讨目前存在的难题,希望有助于C-SCLC的诊疗。With the improvement of people’s understanding of small cell lung cancer and the technology of obtaining pathological specimens, the pathological type suggests that small cell lung cancer mixed with non-small cell lung cancer components has attracted the attention of many researchers, namely compound small cell lung cancer(C-SCLC).Compound small cell lung cancer is a highly malignant tumor. Clinically, it is sensitive to radiotherapy and chemotherapy and has a high remission rate. However, drug resistance and relapse often occur after treatment, with poor prognosis.In recent years, some achievements have been made in the diagnosis and treatment of C-SCLC, but there are still many problems. This paper reviews the research results in this direction at home and abroad, and discusses the existing problems, hoping to contribute to the diagnosis and treatment of C-SCLC.

关 键 词：复合型小细胞肺癌 诊断 外科手术 放射治疗 化学治疗 靶向治疗 免疫治疗 生存率 

分 类 号：R734.2[医药卫生—肿瘤]